Predictors of early response to infliximab in patients with ulcerative colitis
Φόρτωση...
Ημερομηνία
Συγγραφείς
Ferrante, M.
Vermeire, S.
Katsanos, K. H.
Noman, M.
Van Assche, G.
Schnitzler, F.
Arijs, I.
De Hertogh, G.
Hoffman, I.
Geboes, J. K.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Inflamm Bowel Dis
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
BACKGROUND: Our objective is to report the outcome of infliximab (IFX) in ulcerative colitis (UC) patients from a single center and to identify predictors of early clinical response. METHODS: The first 100 UC patients (45 female; median age, 37.9 years) who received IFX at a single center were included. Eighty-four patients received 5 mg/kg IFX, and 37 patients received a 3-dose IFX induction at weeks 0, 2, and 6. The Mayo endoscopic subscore, assessed by sigmoidoscopy before inclusion, was 1, 2, and 3 in 5%, 52%, and 43% of patients, respectively. Sixty percent had pancolitis, 63% were on concomitant immunosuppressive therapy, 9% were active smokers, 64% had C-reactive protein > or =5 mg/dL, and 44% were pANCA+/ASCA-. Five patients received IFX because of severe acute colitis refractory to intravenous corticosteroids. RESULTS: Early complete and partial clinical responses were observed in 41% and 24% of patients. Patients with early clinical response were significantly younger than nonresponders (median age, 35.7 versus 41.6 years, P = 0.041). Patients who were pANCA+/ASCA- had a significantly lower early clinical response (55% versus 76%; odds ratio [OR] = 0.40 (0.16-0.99), P = 0.049). Concomitant immunosuppressive therapy and the use of an IFX induction scheme did not influence early clinical response. Only 1 of 5 patients who received IFX for acute steroid-refractory colitis required colectomy within 2 months. CONCLUSIONS: IFX is an efficient therapy in UC, as shown by 65% early clinical response. A pANCA+/ASCA- serotype and an older age at first IFX infusion are associated with a suboptimal early clinical response.
Περιγραφή
Λέξεις-κλειδιά
Adolescent, Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents/*therapeutic use, Antibodies, Monoclonal/*therapeutic use, Azure Stains, Child, Colitis, Ulcerative/*drug therapy/pathology, Colonoscopy, Female, Gastrointestinal Agents/*therapeutic use, Humans, Male, Middle Aged
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/17206703
http://onlinelibrary.wiley.com/store/10.1002/ibd.20054/asset/20054_ftp.pdf?v=1&t=h0tajn0r&s=9017c15cd0cce21a83c22a46b24d9d06aede5412
http://onlinelibrary.wiley.com/store/10.1002/ibd.20054/asset/20054_ftp.pdf?v=1&t=h0tajn0r&s=9017c15cd0cce21a83c22a46b24d9d06aede5412
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής